Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs. placebo on glucose homeostasis and body composition in 20 post-menopausal women. The recruitment will be performed at Tulane Health Sciences Center.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bazedoxifene/Conjugated Estrogens (BZA/CE) | Experimental | Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with "0.45/20" in black ink on one side. The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications. |
|
| Placebo | Placebo Comparator | Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind. Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with "0.45/20" in black ink on one side. Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bazedoxifene/Conjugated Estrogens (BZA/CE) | Drug | Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Body Mass Index | Body composition will be assessed through change in body mass index at baseline and at 3 months post-treatment. | Change at 3 months from baseline |
| Effect of CE/BZA on Body Composition Using Waist-to-hip Ratio | Body composition will be assessed through change in waist-to-hip ratio at baseline and at 3 months post-treatment. | Change at 3 months from baseline |
| Change in Body Composition Using Dual-energy X-ray Absorptiometry (DXA) | Dual-Energy X-ray Absorptiometry was used to assess body composition. DXA uses an x-ray technique to look at the density of the body and can then estimate the amount of lean muscle mass and fat tissue. Body composition will be assessed through change in DXA body composition at baseline and at 3 months post-treatment. | Change at 3 months from baseline |
| Change in Acute Insulin Response to Glucose (AIRg) | This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in acute insulin response to glucose. IVGTT data derived by MINMOD Millennium software. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Acute Insulin Response (AIRg) to Intravenous Glucose is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model. AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection following glucose administration. A low AIRg indicates decreased ability of the pancreas to secrete insulin. | Change at 3 months from baseline |
| Change in Basal Glucose Concentration (Gb) | This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in basal glucose concentration. IVGTT data derived by MINMOD Millennium software. |
| Measure | Description | Time Frame |
|---|---|---|
| Measure Change in Serum Biomarkers Panel 1 | Systematic inflammation will be measured through change in serum biomarkers (Leptin, Lipocalin 2 (LCN2), plasminogen activator inhibitor-1 (PAI-1), Intact OCN) taken at baseline and 3 months. | Change at 3 months from baseline |
| Measure Change in Serum Biomarkers Panel 2 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Franck Mauvais-Jarvis, MD | Tulane University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tulane University Clinical Translational Unit | New Orleans | Louisiana | 70112 | United States |
At this time there is no plan to share individual participant data (IPD)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Bazedoxifene/Conjugated Estrogens (CE/BZA) | Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. |
| FG001 | Placebo | Participants assigned to placebo will receive a daily tablet that matches the CE/BZA to maintain the blind. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Conjugated Estrogens/Bazedoxifene (CE/BZA) | Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Body Mass Index | Body composition will be assessed through change in body mass index at baseline and at 3 months post-treatment. | Posted | Median | Inter-Quartile Range | Kg/m^2 | Change at 3 months from baseline |
|
The data were collected during baseline visit (during IVGTT for 3 hours) and then again they were collected at the 3 months visit (during IVGTT for 3 hours).
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Bazedoxifene/Conjugated Estrogens (CE/BZA) | Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lower Insulin dose given | Endocrine disorders | Systematic Assessment | During the preparations for IVGTT, incorrect (lower) weight of the subject was used to calculate insulin dose, therefore patient was given lower than recommended insulin dose during IVGTT. This event did not affect patient's wellbeing or health. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Franck Mauvais-Jarvis | Tulane University | 504-988-5990 | fmauvais@tulane.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 26, 2017 | Feb 27, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C447119 | bazedoxifene |
| D004966 | Estrogens, Conjugated (USP) |
| ID | Term |
|---|---|
| D045166 | Estradiol Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo Oral Tablet | Drug | Daily placebo tablet |
|
| Change at 3 months from baseline |
| Change in Disposition Index (DI) | Disposition index (DI) is the product of insulin sensitivity times the amount of insulin secreted in response to blood glucose levels. DI is commonly used as a measure of β-cell function. This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in disposition index (DI). IVGTT data derived by MINMOD Millennium software. DI is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model. DI is the product of insulin sensitivity and the amount of insulin secreted in response to blood glucose levels. Disposition index is used as a measure of beta cell function and the ability of the body to dispose of a glucose load. A low DI is indicative of a higher risk of developing diabetes. | Change at 3 months from baseline |
| Change in Insulin Sensitivity (SI) Index | SI indicates the net capacity for insulin to promote the disposal of glucose and to inhibit the endogenous production of glucose. This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in insulin sensitivity (SI) index. IVGTT data derived by MINMOD Millennium software. SI is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model. SI is a measure of tissue response to circulating insulin in the blood following glucose injection. A low SI signifies low insulin sensitivity and high SI represents high insulin sensitivity. | Change at 3 months from baseline |
| Change in Homeostatic Model Assessment (HOMA) β-cell Function | The homeostasis model assessment of β-cell function (HOMA-β) is an index of insulin secretory function derived from fasting plasma glucose and insulin concentrations. This will be assessed at baseline and 3 months to measure the change in Homeostatic model assessment (HOMA) β-cell function. (HOMA) β-cell function is a method used to quantify beta-cell function from fasting blood samples of insulin and glucose. Normal levels for (HOMA) β-cell function is 107 or more. Lower numbers mean higher risk of developing diabetes. | Change at 3 months from baseline |
| Change in Homeostatic Model Assessment (HOMA) Insulin Resistance (IR) | Homeostatic model assessment (HOMA) is a method for assessing β-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations. This will be assessed at baseline and 3 months to measure the change in Homeostatic model assessment (HOMA) insulin resistance. HOMA IR is a method used to quantify insulin resistance from fasting blood samples of insulin and glucose. Normal levels for HOMA-IR is less than 2.0. Higher levels mean higher risk for developing diabetes. | Change at 3 months from baseline |
| Change in Fasting Insulin Clearance (FIC) | This will be assessed at baseline and 3 months to measure the change in fasting insulin clearance (FIC). FIC derived from fasting C-peptide to insulin ratio. | Change at 3 months from baseline |
| Change in Glucose-stimulated Insulin Clearance (GSIC) | This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in glucose-stimulated insulin clearance (GSIC). GSIC derived from molar ratio of C-peptide to insulin area under curve (AUC) over first 20 min of IVGTT. | Change at 3 months from baseline |
Systematic inflammation will be measured through change in serum biomarkers (Adiponectin, RBP4) taken at baseline and 3 months. |
| Change at 3 months from baseline |
| Measure Change in Leptin:Adiponectin Ratio (LAR) | Systematic inflammation will be measured through change in leptin:adiponectin ratio (LAR) taken at baseline and 3 months. | Change at 3 months from baseline |
| Measure Change in Fibroblast Growth Factor-21 (FGF-21) | Systematic inflammation will be measured through change in Fibroblast growth factor-21 (FGF-21) taken at baseline and 3 months. | Change at 3 months from baseline |
| Measure Change in C-Reactive Protein (CRP) | Systematic inflammation will be measured through change in C-Reactive Protein (CRP) taken at baseline and 3 months. | Change at 3 months from baseline |
| Measure Change in Thiobarbituric Acid Reactive Substance (TBARS) | Systematic inflammation will be measured through change in Thiobarbituric acid reactive substance (TBARS) taken at baseline and 3 months. | Change at 3 months from baseline |
Participants assigned to placebo will receive a daily tablet that matches the CE/BZA to maintain the blind.
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Median | Inter-Quartile Range | Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Years since last menstrual period (LMP) | Median | Inter-Quartile Range | Years |
|
| Waist-to-hip ratio | Median | Inter-Quartile Range | Ratio |
|
| Body Mass Index (BMI) | Median | Inter-Quartile Range | Kg/m^2 |
|
| Waist circumference | Median | Inter-Quartile Range | Cm |
|
| Fasting glucose | Median | Inter-Quartile Range | mg/dL |
|
| Total cholesterol | Median | Inter-Quartile Range | mg/dL |
|
| High-density lipoprotein (HDL) | Median | Inter-Quartile Range | mg/dL |
|
| Low-density lipoprotein (LDL) | Median | Inter-Quartile Range | mg/dL |
|
| Triglycerides | Median | Inter-Quartile Range | mg/dL |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Effect of CE/BZA on Body Composition Using Waist-to-hip Ratio | Body composition will be assessed through change in waist-to-hip ratio at baseline and at 3 months post-treatment. | Posted | Median | Inter-Quartile Range | Ratio | Change at 3 months from baseline |
|
|
|
| Primary | Change in Body Composition Using Dual-energy X-ray Absorptiometry (DXA) | Dual-Energy X-ray Absorptiometry was used to assess body composition. DXA uses an x-ray technique to look at the density of the body and can then estimate the amount of lean muscle mass and fat tissue. Body composition will be assessed through change in DXA body composition at baseline and at 3 months post-treatment. | Posted | Median | Inter-Quartile Range | g | Change at 3 months from baseline |
|
|
|
| Primary | Change in Acute Insulin Response to Glucose (AIRg) | This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in acute insulin response to glucose. IVGTT data derived by MINMOD Millennium software. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Acute Insulin Response (AIRg) to Intravenous Glucose is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model. AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection following glucose administration. A low AIRg indicates decreased ability of the pancreas to secrete insulin. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | uU/l^-1.min^-1 | Change at 3 months from baseline |
|
|
|
| Primary | Change in Basal Glucose Concentration (Gb) | This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in basal glucose concentration. IVGTT data derived by MINMOD Millennium software. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | mg/dL | Change at 3 months from baseline |
|
|
|
| Primary | Change in Disposition Index (DI) | Disposition index (DI) is the product of insulin sensitivity times the amount of insulin secreted in response to blood glucose levels. DI is commonly used as a measure of β-cell function. This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in disposition index (DI). IVGTT data derived by MINMOD Millennium software. DI is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model. DI is the product of insulin sensitivity and the amount of insulin secreted in response to blood glucose levels. Disposition index is used as a measure of beta cell function and the ability of the body to dispose of a glucose load. A low DI is indicative of a higher risk of developing diabetes. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | Index | Change at 3 months from baseline |
|
|
|
| Primary | Change in Insulin Sensitivity (SI) Index | SI indicates the net capacity for insulin to promote the disposal of glucose and to inhibit the endogenous production of glucose. This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in insulin sensitivity (SI) index. IVGTT data derived by MINMOD Millennium software. SI is based on glucose and insulin levels obtained during the frequently sampled intravenous glucose tolerance test and calculated using a mathematical model. SI is a measure of tissue response to circulating insulin in the blood following glucose injection. A low SI signifies low insulin sensitivity and high SI represents high insulin sensitivity. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | uU/L^-1.min^-1 | Change at 3 months from baseline |
|
|
|
| Primary | Change in Homeostatic Model Assessment (HOMA) β-cell Function | The homeostasis model assessment of β-cell function (HOMA-β) is an index of insulin secretory function derived from fasting plasma glucose and insulin concentrations. This will be assessed at baseline and 3 months to measure the change in Homeostatic model assessment (HOMA) β-cell function. (HOMA) β-cell function is a method used to quantify beta-cell function from fasting blood samples of insulin and glucose. Normal levels for (HOMA) β-cell function is 107 or more. Lower numbers mean higher risk of developing diabetes. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | uU/mM | Change at 3 months from baseline |
|
|
|
| Primary | Change in Homeostatic Model Assessment (HOMA) Insulin Resistance (IR) | Homeostatic model assessment (HOMA) is a method for assessing β-cell function and insulin resistance (IR) from basal (fasting) glucose and insulin or C-peptide concentrations. This will be assessed at baseline and 3 months to measure the change in Homeostatic model assessment (HOMA) insulin resistance. HOMA IR is a method used to quantify insulin resistance from fasting blood samples of insulin and glucose. Normal levels for HOMA-IR is less than 2.0. Higher levels mean higher risk for developing diabetes. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | mM.uU/L^-2 | Change at 3 months from baseline |
|
|
|
| Primary | Change in Fasting Insulin Clearance (FIC) | This will be assessed at baseline and 3 months to measure the change in fasting insulin clearance (FIC). FIC derived from fasting C-peptide to insulin ratio. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | Ratio | Change at 3 months from baseline |
|
|
|
| Primary | Change in Glucose-stimulated Insulin Clearance (GSIC) | This will be assessed through an IV Glucose Tolerance Test (IVGTT) conducted at baseline and 3 months to measure the change in glucose-stimulated insulin clearance (GSIC). GSIC derived from molar ratio of C-peptide to insulin area under curve (AUC) over first 20 min of IVGTT. | Note that for technical reasons, the IVGTT serum was processed in only 11 of 12 subjects (CE/BZA n = 6). | Posted | Median | Inter-Quartile Range | Ratio | Change at 3 months from baseline |
|
|
|
| Secondary | Measure Change in Serum Biomarkers Panel 1 | Systematic inflammation will be measured through change in serum biomarkers (Leptin, Lipocalin 2 (LCN2), plasminogen activator inhibitor-1 (PAI-1), Intact OCN) taken at baseline and 3 months. | Posted | Median | Inter-Quartile Range | ng/mL | Change at 3 months from baseline |
|
|
|
| Secondary | Measure Change in Serum Biomarkers Panel 2 | Systematic inflammation will be measured through change in serum biomarkers (Adiponectin, RBP4) taken at baseline and 3 months. | Posted | Median | Inter-Quartile Range | ug/mL | Change at 3 months from baseline |
|
|
|
| Secondary | Measure Change in Leptin:Adiponectin Ratio (LAR) | Systematic inflammation will be measured through change in leptin:adiponectin ratio (LAR) taken at baseline and 3 months. | Posted | Median | Inter-Quartile Range | Ratio | Change at 3 months from baseline |
|
|
|
| Secondary | Measure Change in Fibroblast Growth Factor-21 (FGF-21) | Systematic inflammation will be measured through change in Fibroblast growth factor-21 (FGF-21) taken at baseline and 3 months. | Posted | Median | Inter-Quartile Range | pg/mL | Change at 3 months from baseline |
|
|
|
| Secondary | Measure Change in C-Reactive Protein (CRP) | Systematic inflammation will be measured through change in C-Reactive Protein (CRP) taken at baseline and 3 months. | Posted | Median | Inter-Quartile Range | mg/mL | Change at 3 months from baseline |
|
|
|
| Secondary | Measure Change in Thiobarbituric Acid Reactive Substance (TBARS) | Systematic inflammation will be measured through change in Thiobarbituric acid reactive substance (TBARS) taken at baseline and 3 months. | Posted | Median | Inter-Quartile Range | nmol/mL | Change at 3 months from baseline |
|
|
|
| 0 |
| 7 |
| 0 |
| 7 |
| 0 |
| 7 |
| EG001 | Placebo | Participants assigned to placebo will receive a daily tablet that matches the CE/BZA to maintain the blind. | 0 | 5 | 0 | 5 | 1 | 5 |
|
Not provided
Not provided
Not provided
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006730 |
| Hormones, Hormone Substitutes, and Hormone Antagonists |
| Gynoid fat mass |
|
| Visceral adipose tissue (VAT) mass |
|
| Plasminogen activator inhibitor-1 (PAI-1) |
|
| Osteocalcin (OCN) |
|